Form 4: ADMA Biologics CEO Adam Grossman Sells Shares Following RSU Vesting
SEC Form 4 Filing
ADMA Biologics CEO Adam Grossman sold 48,967 shares of common stock at an average price of $21.10 following the vesting of restricted stock units.
Summary
- Adam Grossman, CEO of ADMA Biologics, sold 48,967 shares of common stock on November 22, 2024.
- The shares were sold at a weighted average price of $21.10, with individual transactions ranging from $21.04 to $21.13.
- The sale occurred after the vesting of restricted stock units (RSUs) granted in 2021.
- Following the transaction, Grossman directly owns 1,989,007 shares of ADMA Biologics common stock.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
- The reported holdings include both vested and unvested RSUs that will convert to common stock over time.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to an executive's stock sale following RSU vesting. It doesn't indicate any positive or negative sentiment about the company's performance or future prospects.
Industry Context
This is a routine Form 4 filing, which is common for executives who receive stock-based compensation. The sale is likely a result of the vesting of previously granted RSUs and is not necessarily indicative of a change in the executive's outlook on the company.
Comparison to Industry Standards
- Executive stock sales following RSU vesting are a common practice across the biotechnology industry.
- Companies like Amgen, Gilead, and Regeneron also see similar filings from their executives.
- The sale by Adam Grossman is within the typical range of such transactions and does not appear to be unusual compared to industry norms.
Stakeholder Impact
- The stock sale may have a minor impact on the share price, but it is unlikely to be significant given the relatively small volume of shares sold compared to the total outstanding shares.
- The sale does not directly impact employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 02/25/2021 | Grant date of 45,788 unvested RSUs that vest quarterly over four years. |
| 09/29/2021 | Grant date of 56,719 unvested time-based RSUs that vest quarterly over two years following December 31, 2022. |
| 09/29/2021 | Grant date of RSUs that vested on June 30, 2024 and September 30, 2024. |
| 03/07/2022 | Grant date of 150,000 unvested RSUs that vest quarterly over four years. |
| 03/06/2023 | Grant date of 430,272 unvested RSUs that vest quarterly over four years. |
| 02/26/2024 | Grant date of 557,728 unvested RSUs that vest quarterly over four years. |
| 06/30/2024 | Vesting date of some of the RSUs granted on September 29, 2021. |
| 09/30/2024 | Vesting date of some of the RSUs granted on September 29, 2021. |
| 11/22/2024 | Date of the stock sale by Adam Grossman. |
| 12/31/2024 | Full vesting date of 56,719 unvested time-based RSUs granted on September 29, 2021. |
Keywords
ADMA Biologics, Adam Grossman, stock sale, restricted stock units, RSU vesting, insider trading, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.